Sort   by:  
 Page size 
TranscriptomicsRNAseq of human cell line RPCI-WM1 comparing artificial PRDM1-targeting miRNA to non-targeting control, and comparing Tazemetostat treatment to DMSO. ChIPseq for the factors BLIMP1 and H3K27me3 in the RPCI-WM1, OPM-2 and NCI-H929 cell lines, along with ChIPseq for EZH2 in the NCI-H929 cell line.
To identify the role of BLIMP1 in Waldenström's macroglobulinemia, the PRDM1 transcript was targeted using an artificial miRNA. RNAseq was used to compare it to a non-targeting control in the RPCI-WM1 cell line. To determine the role of EZH2 in Waldenström's macroglobulinemia, the RPCI-WM1 cell line...
ORGANISM(S): Homo sapiens 
2019-05-07 | E-MTAB-7739 | biostudies-arrayexpress
ProteomicsThe EZH2 inhibitor tazemetostat mitigates HIV immune evasion, reduces reservoir formation, and promotes durable CD8⁺ T-cell revitalization
Persistent HIV reservoirs in CD4⁺ T-cells impede efforts to cure HIV infection. We identified overexpression of enhancer of zeste homolog 2 (EZH2) in HIV-infected CD4⁺ T-cells that survive cytotoxic T lymphocyte (CTL) exposure, suggesting a mechanism of CTL resistance. Inhibition of EZH2 with the FD...
ORGANISM(S): Homo sapiens (Human) 
2026-01-26 | PXD061146 | Pride
Hiv Cd8 t cells Ezh2 Tazemetostat 
TranscriptomicsSingle-cell RNA-seq of LNCaP prostate cancer cells treated with Enzalutamide and Tazemetostat under hypoxic conditions
This experiment investigates the transcriptional landscape of LNCaP prostate cancer cells in response to hormonal and epigenetic therapy under hypoxic conditions using single-cell RNA sequencing (scRNA-seq). The study aims to model drug resistance mechanisms by exposing cells to chronic hypoxia and ...
ORGANISM(S): Homo sapiens 
2025-08-07 | E-MTAB-16057 | biostudies-arrayexpress
GenomicsATAC-seq in SKBR3 cells treated with lapatinib + tazemetostat
ATAC-seq in SKBR3 cells treated with lapatinib + tazemetostat
PRJNA1302430 | ENA
GenomicsSUM149PT cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat)
SUM149PT cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat)
PRJNA847252 | ENA
GenomicsMDA-MB-468 cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat)
MDA-MB-468 cell line treated with AKTi (ipatasertib) and EZH2i (tazemetostat)
PRJNA847253 | ENA
UnknownEvaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer.
Not available
S-EPMC10000745 | biostudies-literature
UnknownThe role of tazemetostat in relapsed/refractory follicular lymphoma.
Not available
S-EPMC8165870 | biostudies-literature
UnknownTargeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat.
Not available
S-EPMC8893153 | biostudies-literature
GenomicsATACseq of TNBC cell lines treated with EZH2i (tazemetostat) and/or AKTi (ipatasertib)
ATACseq of TNBC cell lines treated with EZH2i (tazemetostat) and/or AKTi (ipatasertib)
PRJNA1060317 | ENA
Sort   by:  
 Page size